Gastroparesis Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Published: Oct 2023

Pages: 166

SKU: IRTNTR76697

Snapshot

Gastroparesis Drugs Market 2024-2028

The Gastroparesis Drugs Market size is estimated to grow by USD 1.42 billion at a CAGR of 3.69% between 2023 and 2028.

Key Findings:

The gastroparesis drugs market remained historically at high levels from 2018 to 2023.
The market is segmented into Drug Class, Disease Type, and Geography.
The prokinetic agents sub segment under the drug class segment generated the largest revenue in 2018.
Key regions boosting the market growth include North America, Europe, Asia, and Rest of World (ROW).

Gastroparesis drugs market Share

For More Highlights About this Report, Download Free Sample in a Minute

Gastroparesis Drugs Market: Key Drivers, Trends and Challenges

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Gastroparesis Drugs Market Driver

One of the key factors driving the gastroparesis drugs market growth is the rising global burden of diabetes. The global; burden of diabetes is increasing at a rapid pace. For instance, in 2021, approximately 537 million adults aged 20-79 years had diabetes. In addition, the growing prevalence of Type 1 and Type 2 diabetes increases the chances of gastroparesis significantly.

Moreover, diabetes can harm neurons, including the vagus nerve, as well as unique cells in the stomach wall known as pacemaker cells. In addition, some of the main factors that are causing diabetes include obesity, smoking, a sedentary lifestyle, and growing urbanization. Furthermore, there is an increasing prevalence of diabetes in the older population. Hence, such factors are driving the market growth during the forecast period.

Key Gastroparesis Drugs Market Trends

A key factor shaping the gastroparesis drugs market growth is the increasing number of clinical research. There has been a rapid expansion in the globalization of clinical research over the last two decades. Some of the main factors include organized trials, volunteers, accessibility of qualified local investigators, improved infrastructure facilities, and the low cost of conducting clinical trials in developing nations.

Moreover, the clinical advantages for disease-specific therapeutic incorporate faster and more accurate disease analysis and potential diminishing in sample size and time of clinical trials, which will accelerate drug development. In addition, the NIH-funded GpCRC was initiated to improve the understanding of the pathogenesis and history of gastroparesis and to advance the diagnosis and therapy of patients affected with this condition. Hence, such factors are driving the market growth during the forecast period.

Major Gastroparesis Drugs Market Challenge

Serious side effects of gastroparesis drugs are one of the key challenges hindering the gastroparesis drugs market growth. Prokinetics is the first line of treatment for gastroparesis, which are drugs that increase gastrointestinal motility. In addition, Metoclopramide is one such prokinetic drug and is the only drug approved by the US FDA to treat gastroparesis.

Moreover, it can also aid in relieving nausea by stimulating the contractions of the stomach muscles. In addition, a newer medication, domperidone, with fewer side effects, is also available but with restricted access. Therefore, the serious side effects associated with gastroparesis drugs can negatively impact the market. Hence, it will hinder the market growth during the forecast period.

Gastroparesis Drugs Market Segmentations

Drug Class Segment

The prokinetic agents segment is estimated to witness significant growth during the forecast period. This segment is often employed to aid in addressing the underlying problem of delayed stomach emptying in patients with gastroparesis. One of the main reasons is that these drugs address the fundamental pathophysiology that characterizes gastroparesis, these medications are popularly used in their treatment. In addition, prokinetic medications may not always cause a corresponding change in stomach emptying to match the symptomatic response.

Get a glance at the market contribution of various segments Download the PDF Sample

The prokinetic agents segment was the largest segment and was valued at USD 3.52 billion in 2018. Moreover, several prokinetic medications, such as domperidone and metoclopramide, also have antiemetic qualities. In addition, more recent drugs with limited adverse effects and proven efficacy, such as ghrelin, motilin, 5-HT4 receptor agonists, and dopamine receptors such as metoclopramide, are also being studied in treating gastroparesis. Furthermore, it also comprises agents such as domperidone, erythromycin, and cisapride. Reglan which is a metoclopramide is used for gastroparesis indication in the US and is offered by Ani Pharmaceuticals.

Regional Analysis

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

One of the main factors that significantly contributes to the market growth in North America is the increasing prevalence of diabetes in the region. For example, as per the Centers for Disease Control and Prevention (CDC), in 2022, more than 130 million adults had diabetes in the US. In addition, some of the key regions in North America with the highest proportion of people with diabetes include the US, Canada, and Mexico. Some of the main reasons include unhealthy eating habits and the physically inactive or sedentary lifestyles of people, which leads to obesity. Hence, such factors are driving the market growth in North America during the forecast period.

Key Companies in Gastroparesis Drugs Market

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Abbott Laboratories: The company offers gastroparesis drug such as Ganaton OD and Ganaton.

The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Gastroparesis Drugs Market Scope
Report Coverage	Details
Page number	166
Base year	2023
Historic period	2018 - 2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 3.69%
Market growth 2024-2028	USD 1.42 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	3.53
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 37%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download PDF Sample

What are the Key Data Covered in this Gastroparesis Drugs Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the market between 2024 and 2028
Precise estimation of the size of the market size and its contribution of the market in focus to the parent market
Accurate predictions about upcoming trends and changes in consumer behaviour
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Disease Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global gastroparesis drugs market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global gastroparesis drugs market 2018 - 2022 ($ billion)

4.2 Drug Class Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Drug Class Segment 2018 - 2022 ($ billion)

4.3 Disease Type Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Disease Type Segment 2018 - 2022 ($ billion)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
- Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)

6.2 Comparison by Drug Class
- Exhibit 32: Chart on Comparison by Drug Class
- Exhibit 33: Data Table on Comparison by Drug Class

6.3 Prokinetic agents - Market size and forecast 2023-2028
- Exhibit 34: Chart on Prokinetic agents - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Prokinetic agents - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Prokinetic agents - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Prokinetic agents - Year-over-year growth 2023-2028 (%)

6.4 Antiemetics - Market size and forecast 2023-2028
- Exhibit 38: Chart on Antiemetics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Antiemetics - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Antiemetics - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Antiemetics - Year-over-year growth 2023-2028 (%)

6.5 Botulinum toxin injection - Market size and forecast 2023-2028
- Exhibit 42: Chart on Botulinum toxin injection - Market size and forecast 2023-2028 ($ billion)
- Exhibit 43: Data Table on Botulinum toxin injection - Market size and forecast 2023-2028 ($ billion)
- Exhibit 44: Chart on Botulinum toxin injection - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Botulinum toxin injection - Year-over-year growth 2023-2028 (%)

6.6 Market opportunity by Drug Class
- Exhibit 46: Market opportunity by Drug Class ($ billion)
- Exhibit 47: Data Table on Market opportunity by Drug Class ($ billion)

7 Market Segmentation by Disease Type

7.1 Market segments
- Exhibit 48: Chart on Disease Type - Market share 2023-2028 (%)
- Exhibit 49: Data Table on Disease Type - Market share 2023-2028 (%)

7.2 Comparison by Disease Type
- Exhibit 50: Chart on Comparison by Disease Type
- Exhibit 51: Data Table on Comparison by Disease Type

7.3 Idiopathic gastroparesis - Market size and forecast 2023-2028
- Exhibit 52: Chart on Idiopathic gastroparesis - Market size and forecast 2023-2028 ($ billion)
- Exhibit 53: Data Table on Idiopathic gastroparesis - Market size and forecast 2023-2028 ($ billion)
- Exhibit 54: Chart on Idiopathic gastroparesis - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Idiopathic gastroparesis - Year-over-year growth 2023-2028 (%)

7.4 Diabetic gastroparesis - Market size and forecast 2023-2028
- Exhibit 56: Chart on Diabetic gastroparesis - Market size and forecast 2023-2028 ($ billion)
- Exhibit 57: Data Table on Diabetic gastroparesis - Market size and forecast 2023-2028 ($ billion)
- Exhibit 58: Chart on Diabetic gastroparesis - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Diabetic gastroparesis - Year-over-year growth 2023-2028 (%)

7.5 Post-surgical gastroparesis - Market size and forecast 2023-2028
- Exhibit 60: Chart on Post-surgical gastroparesis - Market size and forecast 2023-2028 ($ billion)
- Exhibit 61: Data Table on Post-surgical gastroparesis - Market size and forecast 2023-2028 ($ billion)
- Exhibit 62: Chart on Post-surgical gastroparesis - Year-over-year growth 2023-2028 (%)
- Exhibit 63: Data Table on Post-surgical gastroparesis - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Disease Type
- Exhibit 64: Market opportunity by Disease Type ($ billion)
- Exhibit 65: Data Table on Market opportunity by Disease Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2023-2028 (%)
- Exhibit 68: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 China - Market size and forecast 2023-2028
- Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)

9.9 Germany - Market size and forecast 2023-2028
- Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.10 UK - Market size and forecast 2023-2028
- Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.11 Japan - Market size and forecast 2023-2028
- Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
- Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
- Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
- Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ billion)
- Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption

11.4 Industry risks
- Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 113: Vendors covered

12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification

12.3 Abbott Laboratories
- Exhibit 115: Abbott Laboratories - Overview
- Exhibit 116: Abbott Laboratories - Business segments
- Exhibit 117: Abbott Laboratories - Key news
- Exhibit 118: Abbott Laboratories - Key offerings
- Exhibit 119: Abbott Laboratories - Segment focus

12.4 AbbVie Inc.
- Exhibit 120: AbbVie Inc. - Overview
- Exhibit 121: AbbVie Inc. - Product / Service
- Exhibit 122: AbbVie Inc. - Key news
- Exhibit 123: AbbVie Inc. - Key offerings

12.5 ANI Pharmaceuticals Inc.
- Exhibit 124: ANI Pharmaceuticals Inc. - Overview
- Exhibit 125: ANI Pharmaceuticals Inc. - Product / Service
- Exhibit 126: ANI Pharmaceuticals Inc. - Key offerings

12.6 Bausch Health Companies Inc.
- Exhibit 127: Bausch Health Companies Inc. - Overview
- Exhibit 128: Bausch Health Companies Inc. - Business segments
- Exhibit 129: Bausch Health Companies Inc. - Key news
- Exhibit 130: Bausch Health Companies Inc. - Key offerings
- Exhibit 131: Bausch Health Companies Inc. - Segment focus

12.7 Cadila Pharmaceuticals Ltd.
- Exhibit 132: Cadila Pharmaceuticals Ltd. - Overview
- Exhibit 133: Cadila Pharmaceuticals Ltd. - Product / Service
- Exhibit 134: Cadila Pharmaceuticals Ltd. - Key offerings

12.8 Eisai Co. Ltd.
- Exhibit 135: Eisai Co. Ltd. - Overview
- Exhibit 136: Eisai Co. Ltd. - Business segments
- Exhibit 137: Eisai Co. Ltd. - Key offerings
- Exhibit 138: Eisai Co. Ltd. - Segment focus

12.9 Evoke Pharma Inc.
- Exhibit 139: Evoke Pharma Inc. - Overview
- Exhibit 140: Evoke Pharma Inc. - Product / Service
- Exhibit 141: Evoke Pharma Inc. - Key offerings

12.10 GlaxoSmithKline Plc
- Exhibit 142: GlaxoSmithKline Plc - Overview
- Exhibit 143: GlaxoSmithKline Plc - Business segments
- Exhibit 144: GlaxoSmithKline Plc - Key news
- Exhibit 145: GlaxoSmithKline Plc - Key offerings
- Exhibit 146: GlaxoSmithKline Plc - Segment focus

12.11 Ipca Laboratories Ltd.
- Exhibit 147: Ipca Laboratories Ltd. - Overview
- Exhibit 148: Ipca Laboratories Ltd. - Product / Service
- Exhibit 149: Ipca Laboratories Ltd. - Key offerings

12.12 Medtronic Plc
- Exhibit 150: Medtronic Plc - Overview
- Exhibit 151: Medtronic Plc - Business segments
- Exhibit 152: Medtronic Plc - Key news
- Exhibit 153: Medtronic Plc - Key offerings
- Exhibit 154: Medtronic Plc - Segment focus

12.13 Otsuka Pharmaceutical Co. Ltd.
- Exhibit 155: Otsuka Pharmaceutical Co. Ltd. - Overview
- Exhibit 156: Otsuka Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 157: Otsuka Pharmaceutical Co. Ltd. - Key offerings

12.14 Pfizer Inc.
- Exhibit 158: Pfizer Inc. - Overview
- Exhibit 159: Pfizer Inc. - Product / Service
- Exhibit 160: Pfizer Inc. - Key news
- Exhibit 161: Pfizer Inc. - Key offerings

12.15 Processa Pharmaceuticals Inc.
- Exhibit 162: Processa Pharmaceuticals Inc. - Overview
- Exhibit 163: Processa Pharmaceuticals Inc. - Product / Service
- Exhibit 164: Processa Pharmaceuticals Inc. - Key offerings

12.16 Takeda Pharmaceutical Co. Ltd.
- Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings

12.17 Vanda Pharmaceuticals Inc.
- Exhibit 169: Vanda Pharmaceuticals Inc. - Overview
- Exhibit 170: Vanda Pharmaceuticals Inc. - Product / Service
- Exhibit 171: Vanda Pharmaceuticals Inc. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 172: Inclusions checklist
- Exhibit 173: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 174: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 175: Research methodology
- Exhibit 176: Validation techniques employed for market sizing
- Exhibit 177: Information sources

13.5 List of abbreviations
- Exhibit 178: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

gastroparesis drugs market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis